Skip to main content
Larimar Therapeutics, Inc. logo

Larimar Therapeutics, Inc. — Investor Relations & Filings

Ticker · LRMR ISIN · US98885E1038 LEI · 529900NCBZHTTJV6HX73 US Professional, scientific and technical activities
Open in API
Filings indexed 666 across all filing types
Latest filing 2017-06-23 Director's Dealing
Country US United States of America
Listing US LRMR

About Larimar Therapeutics, Inc.

https://larimartx.com/

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company utilizes a proprietary intracellular delivery platform to design fusion proteins that deliver therapeutic molecules to targets within cells. Its lead product candidate, nomlabofusp (formerly CTI-1601), is a recombinant fusion protein being evaluated in a Phase 2 clinical program for the treatment of Friedreich's ataxia, a rare and progressive genetic disease. Larimar Therapeutics plans to leverage its platform to develop additional therapies for other rare diseases characterized by deficiencies in intracellular proteins.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2017-06-23 English
FORM 4 SUBMISSION
Director's Dealing
2017-06-23 English
FORM 4 SUBMISSION
Director's Dealing
2017-06-23 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 21, 2017, reporting the submission of matters to a vote of security holders at the company's Annual Meeting of Stockholders. It details the voting results for director elections and ratification of the independent auditor. The content focuses on the official results of shareholder votes at the Annual Meeting, including vote counts for director nominees and auditor ratification. There is no financial data, management discussion, or presentation material included. The document is not a full annual report, earnings release, or proxy statement but specifically reports voting results. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 4091 characters, which is consistent with a detailed voting results announcement rather than a brief notice or a full report.
2017-06-23 English
FORM 4 SUBMISSION
Director's Dealing
2017-05-15 English
FORM 4 SUBMISSION
Director's Dealing
2017-05-11 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.